Angel Angelov
Chief Medical Officer Vistagen
Seminars
Wednesday 3rd February 2027
Exploring if Intranasal Therapies Deliver Clinical Benefit Without Direct Systemic Exposure
9:00 am
- Explore alternative mechanisms through which intranasal therapies may influence CNS pathways and clinical outcomes
- Understand how clinical and translational evidence can support novel nasal mechanisms without relying solely on traditional pharmacokinetic approaches
- Examine lessons learned from developing intranasal therapies targeting neurological and psychiatric disorders
Wednesday 3rd February 2027
Panel Discussion: Has the Industry Finally Solved Nose-to-Brain Delivery?
5:00 pm
- Identify the critical scientific, translational, and clinical evidence gaps that remain before nose-to brain delivery can achieve widespread regulatory acceptance and commercial adoption
- Understand what regulators still need to see regarding reproducibility, biodistribution, imaging, clinical outcomes, and direct CNS exposure before confidently supporting nose-to-brain claims
- Debate whether current preclinical models, analytical tools, imaging technologies, and translational approaches are sufficient to predict human outcomes and support development decisions
- Separate genuine scientific progress from industry hype by examining which technologies, pathways, and approaches are producing meaningful evidence versus those that continue to face significant validation challenges
